BioSpace News Archive

Pharm Country

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea

Teva Pharmaceuticals today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.

June 16, 2021
·
6 min read
X-Ray Detector Market Size to Reach USD 4.19 Billion in 2028, Says Reports and Data

Increasing technological innovation and the launch of effective x-ray equipment such as filmless imaging machines would drive market growth.

June 16, 2021
·
5 min read
Drug Development

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Sirnaomics, Inc., today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company’s lead candidate, STP705, for the treatment of skin squamous cell carcinoma in situ (isSCC).

June 16, 2021
·
6 min read
Deals

Verve Therapeutics Announces Pricing of Initial Public Offering

Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share

June 16, 2021
·
3 min read
Sugar-based Excipients Market Size to Reach USD 1,542.5 Million in 2028, Noted Reports and Data

Increasing use of co-processed excipients to improve dissolution, solubility, bioavailability of drugs, rising demand of generic oral prescribed medications, and technological advancements in sugar-based excipients are some key factors driving market growth.

June 16, 2021
·
5 min read
Wound Care Biologics Market Size to Reach USD 3.71 Billion in 2028, Says Reports and Data

Rising incidence of diabetic foot ulcers, increasing rate of burn injuries, and growing geriatric population and high rate of injuries are some key factors driving market growth.

June 16, 2021
·
5 min read
Deals

Lyell Immunopharma Announces Pricing of Initial Public Offering

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25,000,000 shares of its common stock at a public offering price of $17.00 per share

June 16, 2021
·
2 min read
Genetown

C4 Therapeutics Announces Pricing of Public Offering

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share.

June 16, 2021
·
4 min read
Policy

InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma

InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that the US Food and Drug Administration has granted Orphan Drug Designation to its pan-FGFR inhibitor gunagratinib for the treatment of cholangiocarcinoma.

June 16, 2021
·
2 min read